Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
TOKYO, Jun 22, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today…
Read Moreป้ายกำกับ: lecanemab
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
TOKYO and CAMBRIDGE, Mass., May 10, 2022 – (JCN Newswire via SEAPRWire.com) – …
Read More
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 – (JCN Newswire via SEAPRWire.com) –…
Read More
Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments
CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) –…
Read More
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bi…
Read More
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – …
Read More
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension
TOKYO, Nov 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…
Read More
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
TOKYO, Nov 4, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announ…
Read More
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
TOKYO, Sep 28, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…
Read More
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…
Read More
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
TOKYO, Jun 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…
Read More